- Home
- FMFC vs IRWD Comparison
FMFC vs IRWD Comparison
Compare FMFC & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMFC
- IRWD
- Stock Information
- Founded
- FMFC 2016
- IRWD 1998
- Country
- FMFC Cambodia
- IRWD United States
- Employees
- FMFC N/A
- IRWD N/A
- Industry
- FMFC
- IRWD Biotechnology: Pharmaceutical Preparations
- Sector
- FMFC
- IRWD Health Care
- Exchange
- FMFC NYSE
- IRWD Nasdaq
- Market Cap
- FMFC 116.5M
- IRWD 111.2M
- IPO Year
- FMFC 2025
- IRWD 2010
- Fundamental
- Price
- FMFC $7.22
- IRWD $0.77
- Analyst Decision
- FMFC
- IRWD Buy
- Analyst Count
- FMFC 0
- IRWD 5
- Target Price
- FMFC N/A
- IRWD $4.94
- AVG Volume (30 Days)
- FMFC 580.8K
- IRWD 1.2M
- Earning Date
- FMFC 01-01-0001
- IRWD 08-11-2025
- Dividend Yield
- FMFC N/A
- IRWD N/A
- EPS Growth
- FMFC N/A
- IRWD N/A
- EPS
- FMFC 0.01
- IRWD N/A
- Revenue
- FMFC $17,186,677.00
- IRWD $317,676,000.00
- Revenue This Year
- FMFC N/A
- IRWD N/A
- Revenue Next Year
- FMFC N/A
- IRWD N/A
- P/E Ratio
- FMFC $627.55
- IRWD N/A
- Revenue Growth
- FMFC 3.71
- IRWD N/A
- 52 Week Low
- FMFC $4.20
- IRWD $0.53
- 52 Week High
- FMFC $7.59
- IRWD $6.94
- Technical
- Relative Strength Index (RSI)
- FMFC N/A
- IRWD 49.87
- Support Level
- FMFC N/A
- IRWD $0.76
- Resistance Level
- FMFC N/A
- IRWD $0.95
- Average True Range (ATR)
- FMFC 0.00
- IRWD 0.08
- MACD
- FMFC 0.00
- IRWD -0.00
- Stochastic Oscillator
- FMFC 0.00
- IRWD 36.21
About FMFC KANDAL M VENTURE LIMITED
Kandal M Venture Ltd is engaged in manufacturing affordable luxury leather goods. The company manufactures handbags, such as shoulder bags, crossbody bags, tote bags, backpacks, top-handle handbags, satchels, and other smaller leather goods, such as wallets. Geographically, the company derives maximum revenue from the United States.
About IRWD Ironwood Pharmaceuticals Inc.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.